{"entity":{"id":"nct06542250","kind":"trial","name":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","aka":["TITANium"],"tldr":"A phase 1/2 trial of AZD5492 in advanced solid tumours, run by AstraZeneca, now recruiting.","summary":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. is a phase 1/2 interventional study registered as NCT06542250 by AstraZeneca, with 174 participants planned, started 2024-09-18 and due to reach its primary completion in 2029-12-18. Interventions recorded: AZD5492.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06542250","url":"https://clinicaltrials.gov/study/NCT06542250"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["azd5492"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06542250","phase":"1/2","setting":"A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)","sponsor":"AstraZeneca","participation":[{"nct":"NCT06542250","source":"https://clinicaltrials.gov/study/NCT06542250","fetchedAt":"2026-10-07T16:54:46.480Z","studySha256":"67e0e7d7838e4c0ab703bf4962066096708d1c83b86e8586133cc1506b01412b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-30","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":174,"enrolmentType":"ESTIMATED","siteCount":31,"recruitingSiteCount":30,"countries":["Australia","Canada","China","Denmark","France","Germany","Italy","Japan","Spain","United States"]}],"started":"2024-09-18","startedType":"actual","enrolled":174,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06542250/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"azd5492","kind":"drug","name":"AZD5492","route":"/drugs/azd5492/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}